June 2020
Volume 61, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2020
ANGPTL4 and VEGF cooperate to promote diabetic macular edema.
Author Affiliations & Notes
  • Silvia Montaner Sodhi
    Oncology and Diagnostic Sciences, University of Maryland, Baltimore, Maryland, United States
    Greenebaum Cancer Center, Baltimore, Maryland, United States
  • Deepak Menon
    Oncology and Diagnostic Sciences, University of Maryland, Baltimore, Maryland, United States
  • Tao Ma
    Oncology and Diagnostic Sciences, University of Maryland, Baltimore, Maryland, United States
  • Monika Deshpande
    Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, United States
  • Kathleen Jee
    Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, United States
  • Aumreetam Dinabandhu
    Oncology and Diagnostic Sciences, University of Maryland, Baltimore, Maryland, United States
  • Jordan Vancel
    Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, United States
  • Akrit Sodhi
    Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, United States
  • Footnotes
    Commercial Relationships   Silvia Montaner Sodhi, None; Deepak Menon, None; Tao Ma, None; Monika Deshpande, None; Kathleen Jee, None; Aumreetam Dinabandhu, None; Jordan Vancel, None; Akrit Sodhi, None
  • Footnotes
    Support  R01EY025705
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 305. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Silvia Montaner Sodhi, Deepak Menon, Tao Ma, Monika Deshpande, Kathleen Jee, Aumreetam Dinabandhu, Jordan Vancel, Akrit Sodhi; ANGPTL4 and VEGF cooperate to promote diabetic macular edema.. Invest. Ophthalmol. Vis. Sci. 2020;61(7):305.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Therapies targeting VEGF have had a profound impact on the treatment of patients with diabetic macular edema (DME). However, most patients with DME do not demonstrate a clinically-significant improvement in vision despite treatment with anti-VEGF therapy, suggesting that other vasoactive factors may also contribute its development. Our goal was to identify novel therapeutic strategies for the treatment of DME.

Methods : Cell lines and reagents: Human umbilical vein endothelial cells (HUVECs) and human retinal microvascular endothelial cells (hRECs).
Protein analysis: Western Blot, Immunoprecipitation, Immunofluorescence and ELISA.
Permeability Assays. Passage of FITC-dextran (in vitro) or measurement of extravascular FITC-dextran (in vivo).
Streptozotocin (STZ) mouse model for diabetes.
Human samples. JHU-approved IRB for the acquisition of samples from patients with DME.
Statistical Analysis Two-tailed unpaired Student’s t-test, Mann-Whitney test, or one-way ANOVA with post hoc Tukey HSD.

Results : Expression of the hypoxia-inducible factor (HIF)-1-regulated gene product, angiopoietin-like 4 (ANGPTL4), was increased in the eyes of diabetic mice and in DME patients, and promoted vascular permeability in vitro and in vivo. Moreover, levels of ANGPTL4 in aqueous from DME patients correlated with their ability to promote vascular permeability. We further observed that ANGPTL4 promotion of vascular permeability was independent of, but synergistic with, VEGF. Indeed, exposure of endothelial cells with these two vasoactive factors augmented phosphorylation of the VEGF receptor, KDR, on Tyr951 and Tyr1059, while ANGPTL4 treatment alone stimulated the recycling and intracellular trafficking of KDR. Interestingly, ANGPTL4 did not bind directly to KDR. Rather, we observed that ANGPTL4 binds directly to neuropilins (NRPs) 1 and 2 on endothelial cells (ECs), leading to rapid activation of the RhoA/ROCK signaling pathway, and breakdown of EC-EC junctions. Treatment with a soluble fragment of NRP1 (sNRP1) prevented ANGPTL4 from binding to NRP1, blocked ANGPTL4-induced activation of RhoA, and inhibited EC permeability in vitro and retinal vascular leakage in diabetic mice. sNRP1 further reduced the stimulation of EC permeability by aqueous fluid from patients with DME.

Conclusions : Conclusions:
Our results suggest that therapeutic strategies targeting both ANGPTL4 and VEGF may be an effective approach for the treatment of DME.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×